Clinical Trials / Scientific

Evidence

 

Every Fikzol™ Collagen bottle is backed by human clinical trials

and scientific evidence supporting both safety and efficacy in each

Fikzol™ Collagen capsule, tablet, powder and serving size.

 

Because the Natural Product Industry is now fully regulated, and as

required by the regulatory process, all our human clinical trials and

scientific evidence have been submitted, reviewed and accepted by

Health Canada which further supports and represents all our NPN’s

featured on all our labels.

 

The NPN (Natural Product Number) we proudly feature on each of

our Fikzol™ labels classifies and confirms that all our products contain  

medicinal collagen as the active ingredient and proudly offer effective

therapeutic strength for effective therapeutic use.

 

We encourage you to visit our link titled Medicinal vs Non-Medicinal.

 

Hydrolyzed Collagen Clinical

Study

 

 During the annual congress of the "European League Against

Rheumatism" (EULAR) in Berlin (9th to 12th June 2004), a new

clinical US study was presented showing a signifigant improvement

in knee function in patients with osteoarthritis of the knee after

taking hydrolyzed collagen. An in-vitro study that was also 

presented shows a significant stimulation of cartilage metabolism.

These latest results confirm findings that have been made through

clinical and experimental observation in recent years.

For almost 25 years the effect of hydrolyzed collagen in the treatment

of degenerative joint disease has been investigated. Clinical studies

carried out so far clearly demonstrate the positive influence of hydro-

lyzed collagen in reducing pain and improving joint mobility in

patients with osteoarthritis. Dr. James Rippe, Massachusetts, USA,

in 2004 presented to the EULAR Congress the latest results from

a clinical study which shows improved joint mobility after taking

hydrolyzed collagen.

The randomised, double-blind study (Rippe et. al. submitted for

publication) investigated knee pain, stiffness, joint mobility,

flexibility and development of strength in 190 patients with mild

osteoarthritis of the knee. Over a period of 14 weeks those affected

were given a daily dose of 10 grams of hydrolyzed collagen (plus 300

milligrams of calcium plus 60 milligrams of vitamin C) or placebo.

By using isometric and isokinetic measurements, changes of the

parameters, mentioned above, were determined in the patients. The

results showed a significant improvement in physical joint function. 

The patients that received hydrolyzed collagen developed more

strength in the region of the joint than prior to treatment. These data

illustrate that the ingestion of hydrolyzed collagen can distinctly improve

the functionality of the knee in case of osteoarthritis.

Dr. Steffen Oesser, Collagen Research Institute, Kiel, presented to the

EULAR Congress a further important building block in the research

referring to the mechanism of action of hydrolyzed collagen. In an

in-vitro experiment Oesser was able to show a significant, dose-related

stimulation of type II collagen synthesis in chondrocytes when hydro-

lyzed collagen was added. After the addition of hydrolyzed

collagen there was also a significant increase in pericellular

proteoglycans. In contrast no increase in protease activity was

observed. "These results indicate an increase in synthesis activity

in the whole extracellular matrix of the cartilage. Therefore, hydro-

lyzed collagen has become increasingly important, as far as nu-

trition for individuals with degenerative disease of cartilage

tissue is concerned“, explained Oesser. The new data again confirm

the results of a publication dealing with "bovine" cells which

appeared in the study (Oesser et al. 2003). As early as 1999 a

research group led by Oesser produced evidence of intestinal

absorption of hydrolyzed collagen at an average peptide size

of 3.5 kDa. After absorption collagen fragments accumulated

significantly and exclusively in the joint cartilage.